SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $201 | -56.1% | 9,744 | 0.0% | 0.00% | -50.0% |
Q2 2023 | $458 | +12.0% | 9,744 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $409 | +9.9% | 9,744 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $372 | -99.9% | 9,744 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $382,000 | +21.3% | 9,744 | 0.0% | 0.00% | +50.0% |
Q2 2022 | $315,000 | -2.5% | 9,744 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $323,000 | -22.2% | 9,744 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $415,000 | -3.9% | 9,744 | 0.0% | 0.00% | 0.0% |
Q3 2021 | $432,000 | -22.0% | 9,744 | 0.0% | 0.00% | -33.3% |
Q2 2021 | $554,000 | -25.5% | 9,744 | -2.0% | 0.00% | -25.0% |
Q1 2021 | $744,000 | -13.5% | 9,944 | 0.0% | 0.00% | -20.0% |
Q4 2020 | $860,000 | +72.7% | 9,944 | +22.1% | 0.01% | +25.0% |
Q3 2020 | $498,000 | -26.5% | 8,144 | -50.0% | 0.00% | +33.3% |
Q2 2020 | $678,000 | -39.2% | 16,288 | +16.3% | 0.00% | -89.3% |
Q2 2017 | $1,115,000 | -12.8% | 14,000 | -22.2% | 0.03% | -22.2% |
Q1 2017 | $1,279,000 | – | 18,000 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 1,966,688 | $120,204,000 | 10.81% |
Integral Health Asset Management, LLC | 230,000 | $14,058,000 | 4.30% |
Asymmetry Capital Management, L.P. | 102,462 | $6,262,000 | 4.02% |
ACUTA CAPITAL PARTNERS, LLC | 225,000 | $13,752,000 | 3.74% |
DAFNA Capital Management LLC | 158,306 | $9,676,000 | 3.14% |
Bain Capital Life Sciences Investors, LLC | 499,100 | $30,505,000 | 2.84% |
Boxer Capital, LLC | 1,094,000 | $66,865,000 | 2.31% |
Palo Alto Investors LP | 590,200 | $36,073,000 | 1.98% |
Logos Global Management LP | 250,000 | $15,280,000 | 1.96% |
Bellevue Group AG | 1,579,504 | $96,539,000 | 1.33% |